L3VLUP
ProSign in

LMAT in the 13F filings

Lemaitre Vascular Inc · CUSIP 525558201

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q1 2026Q4 2025Q3 2025Q2 2025Q4 2024Q3 2021Q2 2021Q1 2021Q4 2020Q2 2020Q1 2020Q4 2019
Quarter end
31 Dec 2020
the date the book describes
Filed
16 Feb 2021
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
91
filed both Q3 2020 and Q4 2020; 0 listed it in both
Shares listed
14,897
combined, among listed positions
Reported value
$603k
combined, at the quarter end

Managers listing LMAT in Q4 2020

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2020, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
PDT Partners LLC14,897$603kunder 0.1%Addedn.a.16 Feb 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

No increase among listed positions.

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q1 2021 to 2 in Q1 2026

Tracked managers listing it, at least.

01122201620182019202020212026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
LMAT by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20161$2.9mn.a.n.a.
Q1 20182$1.7mn.a.n.a.
Q2 20181$330kn.a.n.a.
Q3 20182$1.3mn.a.n.a.
Q4 20181$585kn.a.n.a.
Q1 20192$5.8mn.a.n.a.
Q2 20191$808kn.a.n.a.
Q3 20191$1.0mn.a.n.a.
Q4 20191$1.4mn.a.n.a.
Q1 20201$1.7mn.a.n.a.
Q2 20201$2.5mn.a.n.a.
Q4 20201$603kn.a.n.a.
Q1 20211$887kn.a.n.a.
Q2 20211$652kn.a.n.a.
Q3 20211$887kn.a.n.a.
Q4 20241$292kn.a.n.a.
Q2 20251$2.7m10
Q3 20251$2.5m01
Q4 20251$5.1m1112
Q1 20262$3.9m186

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

LMAT and LLY →LMAT and JNJ →LMAT and VRTX →Choose a stock to compare with LMAT →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own LMAT, latest filings →Back to the 13F Explorer →